NeoMega-REALNCT07944638
Real-world Follow-up After Introduction of NeoMega36 Fatty-Acid Supplementation in Extremely Preterm Infants
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 1 version: 1 with changes below.
- Study First Submitted
Endpoints
Primary
Secondary (8)
Show 3 moreShow less
Arms and interventions
Infants born at 22+0 to 27+6 weeks of gestation and cared for at a participating neonatal unit during a defined period before NeoMega36 was introduced into routine care at that unit (European units: preferably 24 months, not overlapping the NeoMega period; Sweden: a defined period before national implementation). Infants received standard nutrition according to local practice.
Infants born at 22+0 to 27+6 weeks of gestation and cared for at a participating neonatal unit during a defined period after NeoMega36 was introduced into routine care at that unit (European units: at least 12 months; Sweden: from national implementation in 2026). All eligible infants in this period are analysed in this group whether or not they individually received NeoMega36; the numbers given and not given the supplement are reported only to describe uptake.
Dietary supplements: Enteral arachidonic acid and docosahexaenoic acid supplement
Sites
1 site in 1 country
- Sahlgrenska Academy, University of GothenburgGothenburg, Sweden